AGT and atrial fibrillation: However, the primary endpoint was almost identical in the two study arms suggesting that potential amlodipine benefits in lowering BP may have been out-balanced by valsartan’s angiotensin-II inhibiting properties.14 Examples of such properties, as previously published from the Value Trial, are less incident atrial fibrillation on valsartan24 and less incident diabetes mellitus.16